DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard tre

Trial Details

NCT ID

NCT07472517

Phase

PHASE3

Sponsor

Boehringer Ingelheim

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

obrixtamig
atezolizumab
carboplatin
etoposide

Locations (sample)

Mobile, Alabama, United States|30.69436,-88.04305
Little Rock, Arkansas, United States|34.74648,-92.28959
Hialeah, Florida, United States|25.8576,-80.27811
Atlanta, Georgia, United States|33.749,-84.38798
Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

Patients with histologically confirmed Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Patients without any previous systematic anti-cancer treatment for ES-SCLC. Patients who received previous systematic anti-cancer treatment during …
Adequate archival formalin-fixed paraffin-embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central labor…
Patients with asymptomatic brain metastasis are eligible if they meet one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →